An Economic Analysis of Erlotinib, Docetaxel, Pemetrexed and Best Supportive Care as Second or Third Line Treatment of Non-Small Cell Lung Cancer
AuthID
P-003-VCG
P-003-VCG
© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service